ESMO 2026 floor digest: the trials generating the most congress buzz
Start here
At the ESMO 2026 congress in October, the conversation on the floor clustered around a handful of studies. The SAFFRON trial drew the most mentions, followed by pembrolizumab-related data. The HARMONI-GI1 and KRASCENDO trials also featured prominently, alongside LITESPARK-011 and LITESPARK-012, the KRASCENDO-1 study, and ivonescimab. The digest, compiled from the congress floor, ranks these eight items by how often they came up, offering a snapshot of where attention is concentrated among attendees. What the rankings reflect is visibility and discussion volume rather than formal impact; details of the underlying results, and how the picture shifts as data are presented and published, are still emerging.
Written by a model from the reports
Coverage timeline
Follow the coverage to see the different angles.
- cba-usa.newsESMO 2026 · 10 2026-10-25 floor digest
1. SAFFRON (36); 2. pembrolizumab (26); 3. HARMONI-GI1 (23); 4. KRASCENDO (22); 5. LITESPARK-011 (16); 6. KRASCENDO-1 (15); 7. ivonescimab (15); 8. LITESPARK-012 (15)
Heat trend for this story
Heat now 5·Peak in the comparable set 10 (Oct 26 12:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.